IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

BACKGROUND: Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy. METHODS: 120 patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Salvatore, Mariantonietta, Pietrantonio, Filippo, Orlandi, Armando, Del Re, Marzia, Berenato, Rosa, Rossi, Ernesto, Caporale, Marta, Guarino, Donatella, Martinetti, Antonia, Basso, Michele, Mennitto, Roberta, Santonocito, Concetta, Mennitto, Alessia, Schinzari, Giovanni, Bossi, Ilaria, Capoluongo, Ettore, Danesi, Romano, de Braud, Filippo, Barone, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370008/
https://www.ncbi.nlm.nih.gov/pubmed/28129643
http://dx.doi.org/10.18632/oncotarget.14810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370008/
https://www.ncbi.nlm.nih.gov/pubmed/28129643
http://dx.doi.org/10.18632/oncotarget.14810

Ejemplares similares